» Articles » PMID: 35454092

Plg-R Expression in Human Breast Cancer Tissues

Overview
Journal Biomolecules
Publisher MDPI
Date 2022 Apr 23
PMID 35454092
Authors
Affiliations
Soon will be listed here.
Abstract

The plasminogen activation system regulates the activity of the serine protease, plasmin. The role of plasminogen receptors in cancer progression is being increasingly appreciated as key players in modulation of the tumor microenvironment. The interaction of plasminogen with cells to promote plasminogen activation requires the presence of proteins exposing C-terminal lysines on the cell surface. Plg-R is a structurally unique plasminogen receptor because it is an integral membrane protein that is synthesized with and binds plasminogen via a C-terminal lysine exposed on the cell surface. Here, we have investigated the expression of Plg-R in human breast tumors and human breast cancer cell lines. Breast cancer progression tissue microarrays were probed with anti-Plg-R mAB and we found that Plg-R is widely expressed in human breast tumors, that its expression is increased in tumors that have spread to draining lymph nodes and distant organs, and that Plg-R expression is most pronounced in hormone receptor (HR)-positive tumors. Plg-R was detected by Western blotting in human breast cancer cell lines. By flow cytometry, Plg-R cell surface expression was highest on the most aggressive tumor cell line. Future studies are warranted to address the functions of Plg-R in breast cancer.

Citing Articles

Identification and validation of genes associated with prognosis of cisplatin-resistant ovarian cancer.

Liu D, Li R, Wang Y, Li D, Li L BMC Cancer. 2024; 24(1):508.

PMID: 39103807 PMC: 11302001. DOI: 10.1186/s12885-024-12264-z.


Distinguishing Plasmin-Generating Microvesicles: Tiny Messengers Involved in Fibrinolysis and Proteolysis.

Plawinski L, Cras A, Hernandez Lopez J, de la Pena A, Van Der Heyden A, Belle C Int J Mol Sci. 2023; 24(2).

PMID: 36675082 PMC: 9860915. DOI: 10.3390/ijms24021571.


A prognostic gene signature for gastric cancer and the immune infiltration-associated mechanism underlying the signature gene, PLG.

Shi H, Duan J, Chen Z, Huang M, Han W, Kong R Clin Transl Oncol. 2022; 25(4):995-1010.

PMID: 36376702 DOI: 10.1007/s12094-022-03003-6.

References
1.
Fay W, Garg N, Sunkar M . Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol. 2007; 27(6):1231-7. DOI: 10.1161/ATVBAHA.107.140046. View

2.
Gonzalez-Jimenez E, Garcia P, Aguilar M, Padilla C, Alvarez J . Breastfeeding and the prevention of breast cancer: a retrospective review of clinical histories. J Clin Nurs. 2013; 23(17-18):2397-403. DOI: 10.1111/jocn.12368. View

3.
Bartick M, Stuebe A, Schwarz E, Luongo C, Reinhold A, Foster E . Cost analysis of maternal disease associated with suboptimal breastfeeding. Obstet Gynecol. 2013; 122(1):111-119. DOI: 10.1097/AOG.0b013e318297a047. View

4.
Duffy M, McGowan P, Harbeck N, Thomssen C, Schmitt M . uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2015; 16(4):428. PMC: 4423643. DOI: 10.1186/s13058-014-0428-4. View

5.
Krajewska M, Zapata J, Meinhold-Heerlein I, Hedayat H, Monks A, Bettendorf H . Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia. 2002; 4(2):129-40. PMC: 1550319. DOI: 10.1038/sj.neo.7900222. View